An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cells.
Biological sciences
Components of the immune system
Immunology
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
20 Jan 2023
20 Jan 2023
Historique:
received:
08
08
2022
revised:
10
11
2022
accepted:
26
12
2022
pubmed:
4
1
2023
medline:
4
1
2023
entrez:
3
1
2023
Statut:
ppublish
Résumé
Spacing the first two doses of SARS-CoV-2 mRNA vaccines beyond 3-4 weeks raised initial concerns about vaccine efficacy. While studies have since shown that long-interval regimens induce robust antibody responses, their impact on B and T cell immunity is poorly known. Here, we compare SARS-CoV-2 naive donors B and T cell responses to two mRNA vaccine doses administered 3-4 versus 16 weeks apart. After boost, the longer interval results in a higher magnitude and a more mature phenotype of RBD-specific B cells. While the two geographically distinct cohorts present quantitative and qualitative differences in T cell responses at baseline and after priming, the second dose led to convergent features with overall similar magnitude, phenotype, and function of CD4
Identifiants
pubmed: 36594081
doi: 10.1016/j.isci.2022.105904
pii: S2589-0042(22)02177-0
pmc: PMC9797215
doi:
Types de publication
Journal Article
Langues
eng
Pagination
105904Subventions
Organisme : NIAID NIH HHS
ID : P01 AI108545
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI155577
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI082630
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI149680
Pays : United States
Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
A.R.G. is a consultant for Relation Therapeutics. E.J.W. is consulting for or is an advisor for Merck, Marengo, Janssen, Related Sciences, Synthekine, and Surface Oncology. E.J.W. is a founder of Surface Oncology, Danger Bio, and Arsenal Biosciences. The other authors have no conflict of interest to declare.
Références
Nat Immunol. 2022 Mar;23(3):380-385
pubmed: 35115679
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Cell Rep. 2022 Jun 28;39(13):111013
pubmed: 35732172
Nature. 2021 Dec;600(7889):517-522
pubmed: 34619745
Nature. 2021 Aug;596(7870):109-113
pubmed: 34182569
Nat Rev Immunol. 2016 Feb;16(2):102-11
pubmed: 26781939
J Exp Med. 2018 Jun 4;215(6):1571-1588
pubmed: 29739835
J Clin Immunol. 2021 Jul;41(5):906-913
pubmed: 33725211
Cell Rep Med. 2020 Oct 20;1(7):100126
pubmed: 33015650
Immunity. 2019 May 21;50(5):1132-1148
pubmed: 31117010
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
J Exp Med. 1998 Nov 2;188(9):1691-703
pubmed: 9802981
Can J Infect Dis Med Microbiol. 2006 Nov;17(6):330-6
pubmed: 18382647
Science. 2021 Dec 03;374(6572):abm0829
pubmed: 34648302
Nature. 2022 Jan;601(7891):110-117
pubmed: 34758478
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
JAMA. 2022 Jan 18;327(3):279-281
pubmed: 34860253
Immunity. 2011 Jan 28;34(1):108-21
pubmed: 21215658
Science. 2021 Oct 08;374(6564):eabh1823
pubmed: 34465633
Cytometry A. 2011 Feb;79(2):167-74
pubmed: 21265010
Genome Biol. 2015 Apr 08;16:67
pubmed: 25887922
Front Immunol. 2022 May 09;13:876306
pubmed: 35615365
N Engl J Med. 2021 Apr 22;384(16):1576-1577
pubmed: 33596348
Cell Rep. 2022 Oct 25;41(4):111554
pubmed: 36244343
J Immunol Methods. 2009 Mar 15;342(1-2):91-7
pubmed: 19133266
Viruses. 2022 Mar 04;14(3):
pubmed: 35336940
Clin Infect Dis. 2021 Dec 6;73(11):2065-2072
pubmed: 33906236
Proc Natl Acad Sci U S A. 1981 Mar;78(3):1800-4
pubmed: 6262826
Front Immunol. 2020 Dec 18;11:606338
pubmed: 33391273
Science. 2010 Feb 26;327(5969):1098-102
pubmed: 20185720
Cell. 2022 Apr 28;185(9):1588-1601.e14
pubmed: 35413241
Science. 2020 Nov 27;370(6520):
pubmed: 32994364
Immunity. 2021 Sep 14;54(9):2133-2142.e3
pubmed: 34453880
Clin Infect Dis. 2022 Nov 30;75(11):1980-1992
pubmed: 35438175
Expert Rev Vaccines. 2008 May;7(4):467-79
pubmed: 18444893
EBioMedicine. 2020 Apr;54:102727
pubmed: 32268275
Ann Intern Med. 2021 Apr;174(4):568-570
pubmed: 33395345
Nat Commun. 2021 Jan 4;12(1):113
pubmed: 33397956
Clin Infect Dis. 2022 Aug 24;75(1):e805-e813
pubmed: 34460902
PLoS One. 2017 Oct 24;12(10):e0186998
pubmed: 29065175
Vaccine. 2021 Dec 3;39(49):7123-7127
pubmed: 34774357
mBio. 2020 Oct 16;11(5):
pubmed: 33067385
Science. 2022 Jan 07;375(6576):43-50
pubmed: 34812653
Ann Intern Med. 2021 Apr;174(4):570-572
pubmed: 33395334
Cell. 2021 Nov 11;184(23):5699-5714.e11
pubmed: 34735795
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
Science. 2020 Oct 2;370(6512):89-94
pubmed: 32753554
Cell Host Microbe. 2022 Jan 12;30(1):97-109.e5
pubmed: 34953513
Cell Rep Med. 2021 Jun 15;2(6):100290
pubmed: 33969322
Immunity. 2018 Oct 16;49(4):725-739.e6
pubmed: 30314758
Nature. 2022 Apr;604(7904):141-145
pubmed: 35168246
EBioMedicine. 2021 Aug;70:103539
pubmed: 34391087
Nat Immunol. 2019 Aug;20(8):1059-1070
pubmed: 31308541
Cell Rep. 2022 Mar 1;38(9):110429
pubmed: 35216664
Pathogens. 2021 Nov 27;10(12):
pubmed: 34959504
Nat Med. 2020 Feb;26(2):222-227
pubmed: 32015556
J Immunol. 2007 May 15;178(10):6624-33
pubmed: 17475894
Lancet. 2021 Sep 11;398(10304):981-990
pubmed: 34480858
Cell Host Microbe. 2021 Jul 14;29(7):1137-1150.e6
pubmed: 34133950